NTLA Stock Recent News
NTLA LATEST HEADLINES
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on August 1, 2025, it awarded an inducement grant to five new employees under Intellia's 2024 Inducement Plan as a material inducement to employment.
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Intellia (NTLA) To Contact Him Directly To Discuss Their Options
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2025 financial results and operational highlights in a conference call on August 7, 2025, at 8 a.m. ET.
An updated edition of the June 27, 2025, article.
Investors often react fast to news. We see it with earnings announcements. And in biotech/pharma, we see it in response to news about drug trials. We saw that in spades on 5/29/25 for gene editor Intellia Therapeutics. The stock lost 29% after news of a “safety concern” surfaced during a Phase III drug trial. The news looked terrible. A lab test showed indications that a patient was experiencing an emergency liver problem. But the asymptomatic condition quickly corrected on its own.
In a recent market update, Goldman Sachs raised its year-end forecast for the S&P 500 (SPX) to 6,900 by year-end, up from a previous ceiling of 6,500, and flagged three stocks investors should have on their radar, including two index stalwarts and one off-the-beaten-path growth opportunity.
Key Points in This Article: The Magnificent 7 transformed markets through AI and digital ecosystems, turning a once-pejorative label into a celebrated symbol of innovation and growth.
CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on July 1, 2025, it awarded an inducement grant to six new employees under Intellia's 2024 Inducement Plan as a material inducement to employment.
NTLA stock surges 29.8% in a month, driven by gene therapy pipeline progress and growing investor attention.
CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.